<DOC>
	<DOCNO>NCT01660672</DOCNO>
	<brief_summary>Pediatric cerebral malaria ( CM ) affect 3 million child year kill ~20 % leave one third survivor long term neurologic psychiatric sequela . Seizures occur commonly CM associate increase risk death neuropsychiatric disability . In Malawi-based , dose- escalation , safety feasibility study enteral levetiracetam pediatric CM , investigator lay groundwork future efficacy study aim improving seizure control ultimately decrease neurologic morbidity pediatric CM .</brief_summary>
	<brief_title>Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria</brief_title>
	<detailed_description>Cerebral malaria ( CM ) affect ~3 million child year , primarily sub-Saharan Africa . Antimalarial medication rapidly clear P. falciparum parasite , mortality rate remain high ( 12-25 % ) . Survivors escape unscathed -- ~30 % experience neurologic sequela include epilepsy , behavioral disorder gross neurologic deficit . Acute seizures occur commonly CM associate high neurologic morbidity mortality . Seizure management malaria endemic region challenge available antiepileptic drug ( AED ) induce respiratory suppression assist ventilation unavailable . More optimal seizure control may improve neurologic outcome pediatric CM survivor , especially medication use affordable deliver safely easily resource limited setting . The investigator propose conduct dose- escalation , safety feasibility study enteral levetiracetam ( LVT ) seizure control child CM seizure admit Queen Elizabeth Central Hospital Blantyre , Malawi . Enteral LVT give via nasogastric tube ( NGT ) rather intravenous ( IV ) formulation use since LVT excellent enteral bioavailability IV formation affordable malaria-endemic region . LVT escalate base upon efficacy toxicity endpoint efficacy define seizure freedom 75 % child 24 hour post LVT administration . Generally , ~20 % child admit CM seizure receive standard AED treatment remain seizure free first 24 hour admission . Safety assessment include monitor problem related NGT placement medication delivery , laboratory parameter 24 hour 7 day post LVT , overall case fatality rate . If efficacy endpoint meet enteral LVT otherwise tolerate , LVT dose ~3 time standard dose use seizure-related condition assess . Pharmacokinetic ( Pk ) data absorption elimination LVT CM obtain since enteral formulation typically use critically ill child malaria show impact drug absorption elimination medication . The safety , feasibility , Pk , optimal dose preliminary efficacy data propose work provide information need determine whether proceed randomize clinical trial LVT pediatric CM patient would include acute seizure control well long term neurologic outcomes critical endpoint . Since enteral LVT relatively affordable short-term use could feasibly deliver resource limited setting , therapy could potentially scale broad use throughout malaria endemic African country</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Malaria , Cerebral</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Comatose Blantyre Comas Score â‰¤ 3 P. falciparum parasitemia Active seizure Serum creatinine &gt; 2mg/dL Preadmission/concomitant treatment antiretroviral medication HIV ( ARVs ) , antituberculous treatment ( ATTs ) , chronic use enzymeinducing medication</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>